By targeting overlapping yet distinct hormonal pathways, dual incretin therapies aim to amplify weight loss, enhance insulin sensitivity, and improve overall metabolic outcomes beyond what is achievable with GLP-1 receptor agonists alone
The clinical relevance to humans remains uncertain, and there is no established link between GLP-1 receptor agonists and thyroid cancer in humans
Rybelsus (Oral Semaglutide): FDA label expansion for cardiovascular risk reduction in Type 2 Diabetes (October 2025)
For patients making decisions today, the comparison is not really Wegovy vs
Honey We only use the highest quality medications and trusted compounded formulations from vetted, US pharmacies that undergo third party testing This level of oversight ensures that your program is safe, personalized, and designed for long-term success and not just a quick fix